Cadrenal Therapeutics, Inc. (CVKD)
$1.02-$0.03 (-2.86%) Latest session
Quang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerQuang X. Pham - OfficerCadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 30,000 | $96K |
24 Form 4 filings on record, the earliest from Aug 27, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Quang X. Pham - Officer | Open-market sale | Common Stock | 7,400 | $3.03 | $22K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 9,029 | $3.05 | $28K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,127 | $3.00 | $6K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 9,167 | $3.55 | $33K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,277 | $3.20 | $7K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,613 | $3.18 | $11K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 513 | $3.16 | $2K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,462 | $4.12 | $6K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 12,996 | $3.94 | $51K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,666 | $3.58 | $13K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 12,992 | $4.06 | $53K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,500 | $4.21 | $15K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 5,893 | $4.38 | $26K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,323 | $4.26 | $10K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,898 | $4.41 | $17K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,064 | $4.42 | $9K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 303 | $5.01 | $2K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 349 | $4.46 | $2K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 6,476 | $5.76 | $37K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,298 | $5.28 | $17K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,989 | $4.93 | $15K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,165 | $5.69 | $7K | |
 Matthew K. Szot - Officer | Open-market sale | Common Stock | 9,933 | $6.97 | $69K | |
| Lee Scott Golden - Director | Grant or award | Stock Options | 5,000 | $0.00 | - | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,129 | $14.03 | $16K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,315 | $13.99 | $18K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,800 | $13.99 | $25K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,800 | $13.99 | $25K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,800 | $14.02 | $25K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,800 | $14.15 | $25K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,693 | $13.99 | $24K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,800 | $14.07 | $25K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 107 | $13.99 | $1K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 500 | $14.13 | $7K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 419 | $14.01 | $6K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 881 | $14.01 | $12K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 100 | $14.00 | $1K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,700 | $13.99 | $24K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 2,581 | $13.99 | $36K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 6,790 | $14.09 | $96K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,500 | $14.00 | $21K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 10,900 | $14.05 | $153K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 3,836 | $13.99 | $54K | |
| Quang X. Pham - Officer | Open-market sale | Common Stock | 1,193 | $13.99 | $17K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 1,600 | $14.00 | $22K | |
| Matthew K. Szot - Officer | Open-market sale | Common Stock | 400 | $14.00 | $6K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Cadrenal Therapeutics, Inc. (CVKD) had 3 insider filings in the last 90 days, with the most recent on 2026-07-02. The full record for CVKD runs to 24 Form 4 filings, the earliest from 2025-08-27. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CVKD were filed in the last 90 days.
5 insider sales of CVKD were filed in the last 90 days, totaling $96K.
This page tracks CVKD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CVKD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
